The therapeutic management of recurrent malignant gliomas (MGs) is not determined. Therefore, the efficacy of a multimodal approach and a combination systemic therapy was investigated. A retrospective analysis of 26 MGs patients at first relapse treated with multimodal therapy (chemotherapy plus surgery and/or reirradiation) or chemotherapy alone was performed. Second-line chemotherapy consisted of fotemustine (FTM) in combination with bevacizumab (BEV) (cFTM/BEV) or followed by third-line BEV (sFTM/BEV). Subgroup analyses were performed. Multimodal therapy provided a higher overall response rate (ORR) (73 vs. 47%), disease control rate (DCR) (82 vs. 67%), median progression-free survival (mPFS) (11 vs. 7 months; P=0.08) and median overall survival (mOS) (13 vs. 8 months; P=0.04) compared with chemotherapy. Concomitant FTM/BEV resulted in higher ORR (84 vs. 36%), DCR (92 vs. 57%), mPFS (10 vs. 5 months; P=0.22) and mOS (11 vs. 5.2 months; P=0.15) compared with sFTM/BEV. Methylated patients did not experience additional survival benefits with multimodality treatment but had higher mPFS (10 vs 7.1 months; P=0.33) and mOS (11 vs. 8 months; P=0.33) with cFTM/BEV. Unmethylated patients experienced the greatest survival benefit with the multimodal approach (mPFS: 10 vs. 5 months; mOS 11 vs 6 months; both P=0.02) and cFTM/BEV (mPFS: 5 vs. 2 months; mOS 6 vs. 3.2 months; both P=0.01). In conclusion, in recurrent MGs, multimodal therapy and cFTM/BEV provide survival and response benefits. Methylated patients benefit from a cFTM/BEV but not from a multimodal approach. Notably, unmethylated patients had the highest survival benefit with the two strategies.

Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy / Prelaj, Arsela; ELENA REBUZZI, Sara; Grassi, Massimiliano; GIRON BERRIOS, JULIO RODRIGO; Pecorari, Silvia; Fusto, Carmela; Ferrara, Carla; Salvati, Maurizio; Stati, Valeria; Tomao, Silverio; Bianco, Vincenzo. - In: MOLECULAR AND CLINICAL ONCOLOGY. - ISSN 2049-9469. - 10:1(2019), pp. 49-57. [10.3892/mco.2018.1745]

Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy

ARSELA PRELAJ
Primo
;
JULIO RODRIGO GIRÒN BERRÌOS;SILVIA PECORARI;CARMELA FUSTO;CARLA FERRARA;MAURIZIO SALVATI;VALERIA STATI;SILVERIO TOMAO
Penultimo
;
2019

Abstract

The therapeutic management of recurrent malignant gliomas (MGs) is not determined. Therefore, the efficacy of a multimodal approach and a combination systemic therapy was investigated. A retrospective analysis of 26 MGs patients at first relapse treated with multimodal therapy (chemotherapy plus surgery and/or reirradiation) or chemotherapy alone was performed. Second-line chemotherapy consisted of fotemustine (FTM) in combination with bevacizumab (BEV) (cFTM/BEV) or followed by third-line BEV (sFTM/BEV). Subgroup analyses were performed. Multimodal therapy provided a higher overall response rate (ORR) (73 vs. 47%), disease control rate (DCR) (82 vs. 67%), median progression-free survival (mPFS) (11 vs. 7 months; P=0.08) and median overall survival (mOS) (13 vs. 8 months; P=0.04) compared with chemotherapy. Concomitant FTM/BEV resulted in higher ORR (84 vs. 36%), DCR (92 vs. 57%), mPFS (10 vs. 5 months; P=0.22) and mOS (11 vs. 5.2 months; P=0.15) compared with sFTM/BEV. Methylated patients did not experience additional survival benefits with multimodality treatment but had higher mPFS (10 vs 7.1 months; P=0.33) and mOS (11 vs. 8 months; P=0.33) with cFTM/BEV. Unmethylated patients experienced the greatest survival benefit with the multimodal approach (mPFS: 10 vs. 5 months; mOS 11 vs 6 months; both P=0.02) and cFTM/BEV (mPFS: 5 vs. 2 months; mOS 6 vs. 3.2 months; both P=0.01). In conclusion, in recurrent MGs, multimodal therapy and cFTM/BEV provide survival and response benefits. Methylated patients benefit from a cFTM/BEV but not from a multimodal approach. Notably, unmethylated patients had the highest survival benefit with the two strategies.
2019
recurrent malignant gliomas; surgery; bevacizumab
01 Pubblicazione su rivista::01a Articolo in rivista
Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy / Prelaj, Arsela; ELENA REBUZZI, Sara; Grassi, Massimiliano; GIRON BERRIOS, JULIO RODRIGO; Pecorari, Silvia; Fusto, Carmela; Ferrara, Carla; Salvati, Maurizio; Stati, Valeria; Tomao, Silverio; Bianco, Vincenzo. - In: MOLECULAR AND CLINICAL ONCOLOGY. - ISSN 2049-9469. - 10:1(2019), pp. 49-57. [10.3892/mco.2018.1745]
File allegati a questo prodotto
File Dimensione Formato  
Prelaj_Multimodal-treatment_2019.pdf

accesso aperto

Note: https://www.spandidos-publications.com/10.3892/mco.2018.1745
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.16 MB
Formato Adobe PDF
1.16 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1191714
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 5
social impact